Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows

The fear of testosterone and prostate cancer traces back to a single experiment from 1941, and understanding why that experiment led medicine down the wrong path for eight decades requires understanding what the prostate actually does with testosterone in the first place.

Charles Huggins observed something real. He took men with advanced metastatic prostate cancer who had been castrated, injected them with testosterone, and watched their cancer markers rise. Castration helped. Testosterone reversed that help. He won the Nobel Prize. And the medical community drew the logical conclusion: if low testosterone slows prostate cancer, then high testosterone must feed it.

That logic was not wrong given what they knew. It was just incomplete.

Here is where the picture was missing a piece. The prostate does not respond to testosterone the way a car responds to gas, where more pedal means more speed indefinitely. It responds more like a sponge. There is a point at which the sponge is fully saturated and adding more water does nothing. The prostate has a finite number of what are called androgen receptors, which are the molecular docking sites that testosterone binds to in order to produce any biological effect. Once those receptors are all occupied, the system is saturated and additional testosterone has nowhere to dock and nothing left to do.

Researchers Morgentaler and Traish mapped this threshold in 2009, and what they found was that prostate androgen receptor saturation happens at approximately 240 to 250 nanograms per deciliter of testosterone. Not 600. Not 800. Two hundred and fifty.

This is what changes everything about the 1941 study.

The men Huggins experimented on were castrated, meaning their testosterone was at or near zero. Taking someone from near zero up to 250 crosses the entire unsaturated zone where the prostate is genuinely sensitive to androgen changes, and the effect is real and measurable. But a man starting TRT does not live in that zone. A man with low testosterone who is symptomatic typically sits somewhere between 200 and 350 nanograms per deciliter. A man on a properly dosed TRT protocol is typically pushed up to somewhere between 500 and 900. Both of those starting points are already above the saturation threshold, which means the additional testosterone from TRT is landing in territory where the prostate is already at maximum androgen exposure and cannot respond further.

Huggins was not wrong that testosterone affected his patients. He was extrapolating into a population his experiment never actually tested.

The research that followed once people started asking the right questions is consistent across very different study designs.

The largest randomized controlled trial on this question followed 5,204 men on TRT versus placebo for 33 months, and prostate cancer developed in 0.46 percent of the testosterone group and 0.42 percent of the placebo group, which produced a hazard ratio of 1.07 and a p-value of 0.87, meaning statistically indistinguishable from chance. A population study tracking 78,615 Finnish men over 18 years found that prostate cancer-specific mortality was actually lower in TRT users, with a hazard ratio of 0.52, meaning roughly half the rate of prostate cancer death compared to non-users. A meta-analysis pooling 28 randomized controlled trials found that PSA, which is a blood marker called prostate-specific antigen used to screen for prostate problems, rose by an average of 0.08 nanograms per milliliter in men on TRT, which is a change so small it falls well within normal daily variation. The same analysis found that urinary symptom scores changed by exactly zero.

None of these numbers suggest a tissue that is being driven toward malignancy.

The most direct test of the original fear, though, is what happens when you give testosterone to men who already have prostate cancer. If testosterone causes or accelerates prostate cancer, giving it to men whose cancer has already been treated should produce a clear signal of recurrence. A study of 69,984 men with treated localized prostate cancer compared 1,012 who subsequently received TRT against those who did not, and found no increase in recurrence and no increase in death. That result is not consistent with a hormone that causes prostate cancer. Cancer does not forget how to be dangerous when researchers are watching.

The practical side of this is straightforward. Before starting TRT, get a baseline PSA drawn so you have a reference point. Check it again at three to six months after starting, and then annually after that. The Endocrine Society's clinical practice guidelines flag a rise of more than 1.4 nanograms per milliliter above your personal baseline as a threshold worth investigating with a urologist. This is not because TRT causes the problem, but because TRT can unmask a cancer that was already developing, just as any hormonal change can accelerate something already in motion. The monitoring catches that early.

The whole arc of this story is really about what happens when a correct observation in a very specific population gets generalized to everyone without testing whether the mechanism actually applies. Huggins saw testosterone affect castrated men with advanced cancer, which was true. The receptor saturation model explains exactly why it was true for them and exactly why it does not extend to men who are nowhere near that physiological floor.

Eighty years of fear, built on an experiment that never tested the people it ended up being applied to.

---

References

1. Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
2. Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
3. Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
4. Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
5. Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
6. Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
7. Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness